CLEOPATRA: A phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer

Clinical Breast Cancer

Volumn 10, Issue 6, 2010, Pages 489-491

  Baselga, Jose ^a   Swain, Sandra M ^b  

^a VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^b WASHINGTON CANCER INSTITUTE   (United States)

Author keywords

HER2:HER3 heterodimer; Pertuzumab; Trastuzumab

Indexed keywords

BIOLOGICAL MARKER; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PERTUZUMAB; PLACEBO; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TAXOID; TUMOR MARKER;

ADULT; ARTICLE; BREAST ADENOCARCINOMA; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ADENOCARCINOMA; BREAST TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG EFFECT; METASTASIS; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; TIME; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79952276644     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.3816/CBC.2010.n.065     Document Type: Article

References (18)

1. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 2005; 10 (suppl 3): 20-9.
2. Mariani G. Breast cancer: New developments in the treatment of metastatic breast cancer: from chemotherapy to biological therapy. Ann Oncol 2005; 16 (suppl 2): ii91-4.
3. Perez EA, Suman VJ, Rowland KM, et al. Two concurrent phase II trials of paclitaxel/ carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer 2005; 6: 425-32. (Pubitemid 43078898)
4. Marty M, Cognetti F, Maraninchi D, et al. Superior long-term survival benefits of trastuzumab plus docetaxel compared to docetaxel alone in patients with HER2-positive metastatic breast cancer: patients surviving more than 4 years in the M77001 study. Breast Cancer Res Treat 2006; 100 (suppl 1): S101.
5. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82. (Pubitemid 17231334)
6. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004; 5: 63-9. (Pubitemid 38821193)
7. Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 2004; 291: 1972-7. (Pubitemid 38544278)
8. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-54. (Pubitemid 40637826)
9. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9: 463-75.
10. Dawood SS, Kristine B, Hortobagyi GN, et al. Prognosis of women with stage IV breast cancer by HER2 status and trastuzumab treatment: An institutional based review. J Clin Oncol 2008; 26 (15 suppl)45s: (abstract 1018).
11. Kataja V, Castiglione M; ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19 (suppl 2): ii11-3.
12. Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000; 19: 3159-67. (Pubitemid 30428195)
13. Tzahar E, Waterman H, Chen X, et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996; 16: 5276-87. (Pubitemid 26315047)
14. Friess T, Juchem R, Scheuer W, et al. Additive antitumor activity by combined treatment with recombinant humanized monoclonal antibody 2C4 and standard chemotherapeutic agents in NSCLC xenografts is independent of HER2 overexpression. Proc Am Soc Clin Oncol 2003; 22: (abstract 953).
15. Lee-Hoeflich ST, Crocker L, Yao E, et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008; 68: 5878-87.
16. Friess T, Scheuer W, Hasmann M. Superior anti-tumour activity after combination treatment with pertuzumab and trastuzumab against NSCLC and breast cancer xenograft tumors. Ann Oncol 2006; 17 (suppl 9): (abstract 96PD).
17. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that had progressed during prior trastuzumab therapy. J Clin Oncol 2010; 28: 1138-44.
18. Portera CC, Walshe JM, Rosing DR, et al. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res 2008; 14: 2710-6